Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma

Clinical Cancer Research

Volumn 3, Issue 10, 1997, Pages 1807-1814

  Tsao, Ming Sound ^a,c   Liu, Ni ^a   Nicklee, Trudey ^a   Shepherd, Frances ^a   Viallet, Jean ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ARTICLE; DIAGNOSTIC VALUE; GENE ACTIVATION; GENE MUTATION; GENETIC LINKAGE; HUMAN; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; TUMOR VASCULARIZATION;

ALLELES; BRONCHI; CAPILLARIES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TRANSFORMED; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENDOTHELIAL GROWTH FACTORS; ENZYME ACTIVATION; GENES, RAS; HUMANS; LUNG NEOPLASMS; LYMPHOKINES; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RNA, MESSENGER; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030771176     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Mountain, C. F. New prognostic factors in lung cancer: biologic prophets of cancer cell aggression. Chest, 108: 246-254, 1995.
2. Moore, D. F., Jr., and Lee, J. S. Staging and prognostic factors: non-small cell lung cancer. In: H. I. Pass, J. B. Mitchell, D. H. Johnson, and A. T. Turrisi (eds.), Lung Cancer: Principles and Practice, pp. 481-494. Philadelphia: Lippincott-Raven Publishers, 1996.
3. Rodenhuis, S., and Slebos, R. J. C. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res., 52 (Suppl.): 2665s-2669s, 1992.
4. Sugio, K., Ishida, T., Yokoyama, H., Inoue, T., Sugimachi, K., and Sasazuki, T. ras gene mutation as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res., 52: 2903-2906, 1992.
5. Mitsudomi, T., Steinberg, S. M., Oie, H. K., Mulshine, J. L., Phelps, R., Viallet, J., Pass, H., Minna, J. D., and Gazdar, A. F. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res., 51: 4999-5002, 1991.
6. Macchiarini, P., Fontanini, G., Hardin, M. J., Squartini, F., and Angeletti, C. A. Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet, 340: 145-146, 1992.
7. Yamazaki, K., Abe, S., Takekawa, H., Sukoh, N., Watanabe, N., Ogura, S., Nakajima, I., Isobe, H., Inoue, K., and Kawakami, Y. Tumor angiogenesis in human lung adenocarcinoma. Cancer (Phila.), 74: 2245-2250, 1994.
8. Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Chine, S., Angeletti, C. A., and Bevilacqua, G. Recurrence and death in non-small cell lung carcinoma: a prognostic model using pathological parameters, microvessel count, and gene protein products. Clin. Cancer Res., 2: 1067-1075, 1996.
9. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. Mutant ras oncogenes up-regulale VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55: 4575-4580, 1995.
10. Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., and Marme, D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem., 270: 25925-25929, 1995.
11. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
12. Risau, W. What, if anything, is an angiogenic factor? Cancer Metastasis Rev., 15: 149-151, 1996.
13. WHO. Histological typing of lung tumors. Am. J. Clin. Pathol., 77: 123-136, 1982.
14. Mountain, C. F. A new international staging system for lung cancer. Chest, 89 (Suppl.): 225s-233s, 1986.
15. Liu, C., and Tsao, M-S. Proto-oncogene and growth factor/receptor expression in the establishment of primary human non-small cell lung carcinoma cell lines. Am. J. Pathol., 142: 413-423, 1993.
16. Wang, N-S., Liu, C., Emond, J., and Tsao, M-S. Annulate lamellae in a large cell lung carcinoma cell line with high expression of tyrosine kinase receptor and proto-oncogenes. Ultrastruct. Pathol., 16: 439-449, 1992.
17. Gazdar, A. F., and Oie, H. K. Re: "Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium" (Letter). Cancer Res., 46: 6011, 1988.
18. Tsao, M-S., Zhu, H., and Viallet, J. Autocrine growth loop of the epidermal growth factor receptor in normal and immortalized human bronchial epithelial cells. Exp. Cell Res., 223: 268-273, 1996.
19. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
20. Rodenhuis, S., Slebos, R. J. C., Boot, A. J. M., Evers, S. G., Mooi, W. J., Wagenaar, S. S., van Bodegom, P. C., and Bos, J. L. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res., 48: 5738-5741, 1988.
21. Slebos, R. J. C., Kibbelaar, R. E., Daleshio, O., Kooistra, A., Stam, J., Meijer, C. J. L. M., Wagenaar, S. S., Vanderschueren, R. G. J. R. A., van Zandwijk, N., Mooi, W. J., Bos, J. L., and Rodenhuis, S. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med., 323: 561-565, 1990.
22. Westra, W. H., Slebos, R. J. C., Offerhaus, G. J. A., Goodman, S. N., Evers, S. G., Kensler, T. W., Askin F. B., Rodenhuis, S., and Hruban, R. H. K-ras oncogene activation in lung adenocarcinomas from former smokers. Cancer (Phila.), 72: 432-438, 1993.
23. Resell, R., Li, S., Skacel, Z., Mate, J. L., Maestre, J., Canela, M., Tolosa, E., Armengol, P., Barnadas, A., and Ariza, A. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene, 8: 2407-2412, 1993.
24. Suzuki, Y., Orita, M., Shiraishi, M., Hayashi, K., and Sekiya, T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene, 5; 1037-1043, 1990.
25. Kobayashi, T., Tsuda, H., Noguchi, M., Hirohashi, S., Shimosato, Y., Goya, T., and Hayata, Y. Association of point mutation in c-Ki-ras oncogene in lung adenocarcinoma with particular reference to cytologic subtypes. Cancer (Phila.), 66: 289-294, 1990.
26. Rosell, R., Molina, F., Moreno, I., Martinez, E., Pifarre, A., Font, A., Li, S., Skacel, Z., Gomez-Codina, J., Camps, C., Monzo, M., and de Anta, J. M. Mutated K-ras gene analysis in a randomized trial of pre-operative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. Lung Cancer, 12 (Suppl. 1): s59-s70, 1995.
27. Vachtenheim, J., Horáková, I., Novotná, H., Opálka, P., and Roubková, H. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Clin. Cancer Res., 1: 359-365, 1995.
28. Mitsudomi, T., Viallet, J., Mulshine, J. L., Linnoila, R. I., Minna, J. D., and Gazdar, A. F. Mutations of ras genes distinguish a subset of non-small cell lung cancer cell lines from small cell lung cancer cell lines. Oncogene, 6: 1353-1362, 1991.
29. Westra, W. H., Baas, I. O., Hruban, R. H., Askin, F. B., Wilson, K., Offerhaus, G. J. A., and Slebos, R. J. C. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res., 56: 2224-2228, 1996.
30. Sarkar, F. H., Valdivieso, M., Borders, J., Yao, K-L., Raval, M. M. T., Madan, S. K., Sreepathi, P., Shimoyama, R., Steiger, Z., Visscher, D. W., and Crissman, J. D. A universal method for the mutational analysis of K-ras and p53 gene in non-small cell lung cancer using formalin-fixed paraffin-embedded tissue. Diagn. Mol. Pathol., 4: 266-273, 1995.
31. Keohavong, P., DeMichele, M. A. A., Melacrinos, A. C., Landreneau, R. J., Weyant, R. J., and Siegfried, J. M. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin. Cancer Res., 2: 411-418, 1996.
32. Mills, N. E., Fishman, C. L., Rom, W. N., Dubin, N., and Jacobson, D. R. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res., 55: 1444-1447, 1995.
33. Srivastava, A., Laidler, P., Davies, R., Horgan, K., and Hughes, L. E. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0-mm thick) skin melanoma. Am. J. Pathol., 133: 419-423, 1988.
34. Gasparini, G., and Harris, A. L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J. Clin. Oncol., 13: 765-782, 1995.
35. Weidner, N. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol., 147: 9-19, 1995.
36. Charpin, C., Devictor, B., Bergeret, D., Andrac, L., Boulat, J., Horschowski, N., Lavaut, M. N., and Piana, L. CD31 quantitative immunocytochemical assays in breast carcinomas. Am. J. Clin. Pathol., 103: 443-448, 1995.
37. Visscher, D. W., Smilanetz, S., Drozdowicz, S., and Wykes, S. M. Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal. Quant. Cytol. Histol., 15: 88-92, 1993.
38. Warren, R. S., Yuan, H., Matli, M. R., Ferrara, N., and Donner, D. B. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem., 271: 29483-29488, 1996.
39. Koukourakis, M. I., Giatromanolaki, A., O'Byrne, K. J., Comley, M., Whitehouse, R. M., Talbot, D. C., Gatter, K. C., and Harris, A. L. Platelet-derived endothelial cell growth factor expression correlates with tumor angiogenesis and prognosis in non-small cell lung cancer. Br. J. Cancer, 75: 477-481, 1997.